FI920342L - Komplex som innehaoller koaguleringsfaktor ix och foerfarande foer framstaellning daerav. - Google Patents

Komplex som innehaoller koaguleringsfaktor ix och foerfarande foer framstaellning daerav. Download PDF

Info

Publication number
FI920342L
FI920342L FI920342A FI920342A FI920342L FI 920342 L FI920342 L FI 920342L FI 920342 A FI920342 A FI 920342A FI 920342 A FI920342 A FI 920342A FI 920342 L FI920342 L FI 920342L
Authority
FI
Finland
Prior art keywords
koaguleringsfaktor
komplex
foerfarande foer
foer framstaellning
och foerfarande
Prior art date
Application number
FI920342A
Other languages
English (en)
Other versions
FI920342A0 (fi
FI100111B (fi
Inventor
Yendra Linnau
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of FI920342A0 publication Critical patent/FI920342A0/fi
Publication of FI920342L publication Critical patent/FI920342L/fi
Application granted granted Critical
Publication of FI100111B publication Critical patent/FI100111B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Measurement Of Velocity Or Position Using Acoustic Or Ultrasonic Waves (AREA)
FI920342A 1991-01-25 1992-01-24 Hyytymistekijää IX sisältävä kompleksi ja menetelmä sen valmistamiseks i FI100111B (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0016391A AT402261B (de) 1991-01-25 1991-01-25 Komplex enthaltend den gerinnungsfaktor ix

Publications (3)

Publication Number Publication Date
FI920342A0 FI920342A0 (fi) 1992-01-24
FI920342L true FI920342L (fi) 1992-07-26
FI100111B FI100111B (fi) 1997-09-30

Family

ID=3483232

Family Applications (1)

Application Number Title Priority Date Filing Date
FI920342A FI100111B (fi) 1991-01-25 1992-01-24 Hyytymistekijää IX sisältävä kompleksi ja menetelmä sen valmistamiseks i

Country Status (12)

Country Link
US (2) US5281661A (fi)
EP (1) EP0496725B1 (fi)
JP (2) JP2651307B2 (fi)
AT (2) AT402261B (fi)
CA (1) CA2059979C (fi)
CZ (2) CZ154794A3 (fi)
DE (1) DE59207638D1 (fi)
DK (1) DK0496725T3 (fi)
ES (1) ES2098485T3 (fi)
FI (1) FI100111B (fi)
HU (1) HU212362B (fi)
SK (2) SK280130B6 (fi)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3418621B2 (ja) * 1991-03-01 2003-06-23 アヴェンティス ベーリング エルエルシー Ｉｘ因子の調製
DE4342132C1 (de) * 1993-12-10 1994-11-03 Octapharma Ag Verfahren zur Herstellung virusinaktivierte Vitamin K abhängige Plasmakomponenten sowie Protein C und Protein S enthaltender Mittel durch Membran-Chromatographie
ATE208493T1 (de) 1994-06-30 2001-11-15 Dade Behring Inc Bioaktive poröse trennteile
US5888826A (en) * 1994-06-30 1999-03-30 Dade Behring Inc. Combination reagent holding and test device
US5602037A (en) * 1994-06-30 1997-02-11 Dade International, Inc. Combination reagent holding and test device
DE19506633A1 (de) * 1995-02-25 1996-08-29 Octapharma Ag Verfahren zur Herstellung von Faktor IX aus biologischen Quellen
US5714583A (en) * 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
US5958716A (en) * 1996-06-06 1999-09-28 Dade Behring Inc. Blood factor assay
EP1029546A1 (en) * 1997-11-05 2000-08-23 Yoshitomi Pharmaceutical Industries, Ltd. Heparin cofactor ii preparations and process for producing the same
JP4855074B2 (ja) * 2003-09-30 2012-01-18 一般財団法人化学及血清療法研究所 高純度血液凝固ｉｘ因子調製物およびその精製方法
JP2008505119A (ja) * 2004-06-30 2008-02-21 ネクター セラピューティクス アラバマ，コーポレイション 高分子−第ｉｘ因子部分の抱合体
EP1831242B1 (en) * 2004-12-23 2012-09-26 Novo Nordisk Health Care AG Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest
US8546548B2 (en) 2009-05-27 2013-10-01 Baxter International Inc. Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
PT2477603E (pt) 2009-09-17 2016-06-16 Baxalta Inc Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização
PL2616090T3 (pl) 2010-09-17 2023-12-18 Takeda Pharmaceutical Company Limited Stabilizowanie immunoglobulin poprzez wodną formulację z histydyną o ph od słabo kwaśnego do obojętnego
EP2652491B1 (en) 2010-12-15 2017-11-29 Baxalta GmbH Eluate collection using conductivity gradient
AU2012254169B2 (en) 2011-02-25 2016-02-25 Wellstat Diagnostics, Llc Assays for detecting enzymatic activity
AU2024351533A1 (en) 2023-09-26 2026-03-19 Takeda Pharmaceutical Company Limited IMMUNOGLOBULIN FORMULATIONS DEPLETED IN IgA

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2543448A1 (fr) * 1983-04-01 1984-10-05 Rhone Poulenc Spec Chim Procede de fractionnement du plasma
US4820805A (en) * 1983-07-14 1989-04-11 New York Blood Center, Inc. Undenatured virus-free trialkyl phosphate treated biologically active protein derivatives
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US4721572A (en) * 1985-07-12 1988-01-26 Miles Laboratories, Inc. Purfication of blood clotting factors and other blood proteins on non-carbohydrate sulfated matrices
EP0229026B1 (en) * 1986-01-06 1995-11-22 Blood Systems Inc, an Arizona not-for-profit corporation Therapeutic blood product, means and methods of preparing same
JPS63108000A (ja) * 1986-05-15 1988-05-12 Green Cross Corp:The 第８因子の精製方法
US4725673A (en) * 1986-08-29 1988-02-16 Alpha Therapeutic Corporation Plasma fraction purification using silica resin bound to a ligand
ES2045167T5 (es) * 1987-10-23 1996-07-01 Centre Regional De Transfusion Preparacion de concentrado de factor ix humano de elevada pureza y de otras proteinas plasmaticas.
DE3914869C1 (fi) * 1989-05-05 1990-08-09 Biotest Pharma Gmbh, 6072 Dreieich, De

Also Published As

Publication number Publication date
JP2651307B2 (ja) 1997-09-10
HU212362B (en) 1996-06-28
JPH08259449A (ja) 1996-10-08
HUT63863A (en) 1993-10-28
US5409990A (en) 1995-04-25
EP0496725A3 (en) 1993-05-05
CZ280297B6 (cs) 1995-12-13
EP0496725B1 (de) 1996-12-11
FI920342A0 (fi) 1992-01-24
ATA16391A (de) 1996-08-15
SK280989B6 (sk) 2000-10-09
HU9200225D0 (en) 1992-04-28
CZ280725B6 (cs) 1996-04-17
CA2059979C (en) 2003-04-15
US5281661A (en) 1994-01-25
AT402261B (de) 1997-03-25
DE59207638D1 (de) 1997-01-23
DK0496725T3 (da) 1997-06-09
ATE146220T1 (de) 1996-12-15
FI100111B (fi) 1997-09-30
JP2866047B2 (ja) 1999-03-08
CZ154794A3 (en) 1996-04-17
EP0496725A2 (de) 1992-07-29
CS21192A3 (en) 1992-08-12
SK280130B6 (sk) 1999-08-06
ES2098485T3 (es) 1997-05-01
CA2059979A1 (en) 1992-07-26
JPH04295432A (ja) 1992-10-20

Similar Documents

Publication Publication Date Title
FI913738A7 (fi) Oximkarbamater och oximkarbonater som luftroersutvidgande och antiinflammatoriska aemnen.
FI921952A0 (fi) Foerfarande foer framstaellning av dialkylenpiperidinofoereningar och enantiomerer daerav anvaendbara som laekemedel.
FI925735L (fi) Polymerer och oligomerer av gallsyraderivat, foerfarande foer deras framstaellning och deras anvaendning som laekemedel
FI914619A7 (fi) Hydroxylfunktionaliserade polyeteraminer som barriaerfoerpackning foer syrekaensliga materialer.
FI914796L (fi) Omaettade hydroxialkylkinolinsyror som leukotrienantagonister.
FI893105A0 (fi) Tryckkapsel foer spraybehaollare och spraybehaollare som utnyttjar en saodan kapsel.
FI914596L (fi) Biaxialt orienterad polypropylenfolie avsedd som foerpackningsomslag.
FI921182A0 (fi) Velangummi som snabbt hydratiseras.
FI910993A7 (fi) Hjaelpmedel som foerbaettrar glidegenskaper.
FI914004A0 (fi) Epoxifunktionella siloxanhartskopolymerer som loesgoeringsreglerande tillaeggsaemnen.
FI915357A0 (fi) Optisk bakskiva som foerbinder kretskort.
FI914797L (fi) Maettade hydroxialkylkinolinsyror som leukotrienantagonister.
FI923558A0 (fi) Tetrahydroindazol-, tetrahydrocyklo -pentapyrazol- och hexahydrocykloheptapyrazolfoereningar och deras anvaendning som inhibitorer av hmg-coa-reduktas.
FI920271L (fi) Polyamintioler som straolningsskyddande aemnen.
FI923756A0 (fi) Polyolefinkompositioner som omfattar glycerolmonoestrar av c20-24-fettsyror och daerav framstaellda skumprodukter.
FI923185A0 (fi) Foerfarande och anordning foer framstaellning av fogloesa band- och traodoeglor och deras anvaendning som kapverktyg i band- och traodsaogar.
FI923382A7 (fi) Laosanordning som omfattar nyckel och laoscylinder
FI912468A0 (fi) Oxidantkaensliga och -okaensliga aromatiska estrar som inhibitorer foer humant neutrofilelastas.
FI913201A7 (fi) Ymppolysackarider, deras framställningsförfarande och deras användning som sekvesteringsagenter
FI915568L (fi) Polyamidhartskompositioner foer anvaendning som bindemedel foer laminerande tryckfaergshartser.
FI921974A0 (fi) Lageranlaeggning och undervattens- drivkraftsenhet som innehaoller den.
FI921596A0 (fi) Tetron- och tietetronsyraderivat och fosfolifas a2 som inhibitorer.
FI913657A7 (fi) 4-amino-d4-steroider och deras anvaendning som 5a-reduktasinhibitorer.
FI923841A7 (fi) Substituerade mandelsyraderivat, foerfarande foer deras framstaellning och deras anvaendning som laekemedel
FI933376L (fi) 4-amino-3-acylkinolinderivater och deras anvaendning som inhibitorer avmagsyrasekretion